LONDON, March 21, 2014 /PRNewswire/ --
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ
Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial
Average ending the session at 16,331.05, up 0.67% and the S&P
500 edging 0.60% higher to finish the trading session at 1,872.01.
During the session, gains in the Information Technology,
Financials, and Telecommunication Services sectors positively
impacted the broader market. A number of stocks saw large
movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP),
Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst
Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd
(NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA
can be downloaded upon signing up at:
http://www.investor-edge.com/387-register
On Thursday, shares in ZIOPHARM Oncology Inc. ended the session at
$5.42, up 11.75%, hitting a new
52-week high of $5.58. A total of
3.42 million shares were traded as compared to a three months
average volume of 1.05 million shares. During the session, the
stock traded between $5.15 and $5.58.
ZIOPHARM Oncology Inc.'s shares have advanced 26.05% in the last
one month, 35.50% in the previous three months and 24.88% on YTD
basis. The S&P 500 Health Care Sector Index mapped a loss of
0.02% during the trading session and charted up 0.77% in the last
one month. Further, the stock is trading at a Relative Strength
Index (RSI) of 63.24 and trading above its 50-day and 200-day
moving averages of $4.40 and
$3.59, respectively. Sign up today to
read free research on ZIOP at:
http://www.investor-edge.com/387-ZIOP-.pdf
Shares in Centrais Eletricas Brasileiras SA edged 4.64% higher,
finishing Thursday's session at $2.48. The stock fluctuated between $2.36 and $2.65 during the session with a trading
volume of 2.93 million shares as compared to a three months average
volume of 1.10 million shares. Shares in Centrais Eletricas
Brasileiras SA have gained 15.89% in the previous three trading
sessions and 20.39% in the last one month, while the same has
fallen by 4.25% on YTD basis. The S&P 500 Utilities Sector
Index mapped a gain of 0.10% during the trading session and charted
up 6.11% in previous three months. Furthermore, the stock is
trading at an RSI of 63.02 and trading above its 50-day and 200-day
moving averages of $2.20 and
$2.43, respectively. Sign up today to
read free research on EBR at:
http://www.investor-edge.com/387-EBR-.pdf
Shares in Catalyst Pharmaceutical Partners Inc. closed Thursday's
session at $2.39, which is 6.22%
higher than the previous day's closing price of $2.25. A total of 2.84 million shares were traded
as compared to a three months average volume of 0.91 million
shares. The stock oscillated between $2.21
and $2.50 during the trading session. Shares in Catalyst
Pharmaceutical Partners Inc. have surged 11.68% in the previous
three trading sessions, 27.13% in the last three months and 22.56%
on YTD basis. The S&P 500 Health Care Sector Index mapped a
loss of 0.02% during the trading session and charted up 7.91% in
the previous three months. Moreover, the stock is trading at an RSI
of 59.70 and trading above its 50-day and 200-day moving averages
of $2.05 and $1.82, respectively. Sign up today to read free
research on CPRX at:
http://www.investor-edge.com/387-CPRX-.pdf
Sinovac Biotech Ltd's stock finished Thursday's session at
$8.07, up 17.13%, recording a new
52-week high of $8.09. A total of
4.88 million shares were traded which is above the three months
average volume of 0.34 million shares. The stock vacillated between
$7.16 and $8.09 during the session
and traded at a PE ratio of 67.25. Sinovac Biotech Ltd's shares
have rallied 21.54% in the last one month and 31.86% on YTD basis.
The S&P 500 Health Care Sector Index mapped a loss of 0.02%
during the trading session and charted up 0.78% in the previous
three trading sessions. Additionally, the stock is trading at an
RSI of 61.32 and trading above its 50-day and 200-day moving
averages of $6.53 and $5.56, respectively. Sign up today to read free
research on SVA at:
http://www.investor-edge.com/387-SVA-.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge